港股异动 | 和誉-B(02256)涨超4%续创新高 上半年业绩快速增长 花旗称公司现估值偏低

智通财经
Aug 11, 2025

智通财经APP获悉,和誉-B(02256)涨超4%,高见12.89港元续创历史新高。截至发稿,涨4.63%,报12.87港元,成交额5376.31万港元。

消息面上,近日,和誉公布中期业绩,公司上半年实现收入6.12亿元,同比增长21.5%;归母净利润3.28亿元,同比增长58.8%。此外,自2025 年3 月起,公司持续推出并实施回购计划,截止2025 年上半年末,共回购954.5万股股份,占年初发行股份总数的1.4%,累计涉及资金7530万港元。中金表示,公司业绩超预期,主要由于默克行权收入超预期。公司指引全年经营活动消耗资金在5.7亿元人民币以内,预计公司全年有望维持盈利。

花旗认为,和誉现估值偏低,基于其2款晚期候选药pimicotinib与irpagratinib都具高度确定性,且差异化创新管线有望实现对外授权。该行预期irpagratinib二线肝细胞癌三期临床试验的成功率极高,其估值应被纳入考量因素。另外,该行认为和誉在2025及2026年将会有关键催化剂出现,关注其pimicotinib上市审批及商业化表现、irpagratinib三期数据公布,以及ABSK043及ABSK061等多项候选药物的数据更新,和潜在的商业合作。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10